Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment.

IMPORTANCE To understand how a model of Alzheimer disease pathophysiology based on β-amyloidosis and neurodegeneration predicts the regional anatomic expansion of hypometabolism and atrophy in persons with mild cognitive impairment (MCI). OBJECTIVE To define the role of β-amyloidosis and neurodegeneration in the subsequent progression of topographic cortical structural and metabolic changes in MCI. DESIGN, SETTING, AND PARTICIPANTS Longitudinal, observational study with serial brain imaging conducted from March 28, 2006, to January 6, 2015, using a population-based cohort. A total of 96 participants with MCI (all aged >70 years) with serial imaging biomarkers from the Mayo Clinic Study of Aging or Mayo Alzheimer's Disease Research Center were included. Participants were characterized initially as having elevated or not elevated brain β-amyloidosis (A+ or A-) based on 11C-Pittsburgh compound B positron emission tomography. They were further characterized initially by the presence or absence of neurodegeneration (N+ or N-), where the presence of neurodegeneration was defined by abnormally low hippocampal volume or hypometabolism in an Alzheimer disease-like pattern on 18fluorodeoxyglucose (FDG)-positron emission tomography. MAIN OUTCOMES AND MEASURES Regional FDG standardized uptake value ratio (SUVR) and gray matter volumes in medial temporal, lateral temporal, lateral parietal, and medial parietal regions. RESULTS In the primary regions of interest (ROI), the A+N+ group (n = 45) had lower FDG SUVR at baseline compared with the A+N- group (n = 17) (all 4 ROIs; P < .001). The A+N+ group also had lower FDG SUVR at baseline (all 4 ROIs; P < .01) compared with the A-N- group (n = 12). The A+N+ group had lower medial temporal gray matter volume at baseline (P < .001) compared with either the A+N- group or A-N- group. The A+N+ group showed large longitudinal declines in FDG SUVR (P < .05 for medial temporal, lateral temporal, and medial parietal regions) and gray matter volumes (P < .05 for medial temporal and lateral temporal regions) compared with the A-N+ group (n = 22). The A+N+ group also showed large longitudinal declines compared with the A-N- group on FDG SUVR (P < .05 for medial temporal and lateral parietal regions) and gray matter volumes (all 4 ROIs; P < .05) compared with the A+N- group. The A-N+ group did not show declines in FDG SUVR or gray matter volume compared with the A+N- or A-N- groups. CONCLUSIONS AND RELEVANCE Persons with MCI who were A+N+ demonstrated volumetric and metabolic worsening in temporal and parietal association areas, consistent with the expectation that the MCI stage in the Alzheimer pathway heralds incipient isocortical involvement. The A-N+ group, those with suspected non-Alzheimer pathophysiology, lacked a distinctive longitudinal volumetric or metabolic profile.

[1]  Michael J Leach,et al.  Longitudinal , 2015, The Medical journal of Australia.

[2]  Matthew L Senjem,et al.  Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. , 2015, JAMA neurology.

[3]  Stephen F. Carter,et al.  Mild cognitive impairment with suspected nonamyloid pathology (SNAP) , 2015, Neurology.

[4]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[5]  C. Jack,et al.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study , 2014, The Lancet Neurology.

[6]  D. Knopman.  β-Amyloidosis and neurodegeneration in Alzheimer disease , 2014, Neurology.

[7]  Clifford R. Jack,et al.  Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration , 2014, Neurology.

[8]  Bixente Dilharreguy,et al.  Time course of brain volume changes in the preclinical phase of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[9]  D. Bennett,et al.  A 2-process model for neuropathology of Alzheimer's disease , 2014, Neurobiology of Aging.

[10]  V. Pankratz,et al.  Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal , 2014, Neurology.

[11]  W. M. van der Flier,et al.  Preclinical AD predicts decline in memory and executive functions in subjective complaints , 2013, Neurology.

[12]  C. Jack,et al.  Mild cognitive impairment due to Alzheimer disease in the community , 2013, Annals of neurology.

[13]  C. Jack,et al.  Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. , 2013, JAMA neurology.

[14]  C. Jack,et al.  Brain injury biomarkers are not dependent on β‐amyloid in normal elderly , 2013, Annals of neurology.

[15]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[16]  Stephen F. Carter,et al.  Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease , 2013, Neurology.

[17]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[18]  Bradford C. Dickerson,et al.  Regional Expansion of Hypometabolism in Alzheimer's Disease Follows Amyloid Deposition with Temporal Delay , 2012, Biological Psychiatry.

[19]  E G Tangalos,et al.  The incidence of MCI differs by subtype and is higher in men , 2012, Neurology.

[20]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[21]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[22]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  Charles D. Smith,et al.  Hippocampal sclerosis in advanced age: clinical and pathological features. , 2011, Brain : a journal of neurology.

[24]  R. Killiany,et al.  Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults , 2011, Neurology.

[25]  Norbert Schuff,et al.  Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. , 2011, Brain : a journal of neurology.

[26]  D. Grobbee,et al.  The (mis)use of overlap of confidence intervals to assess effect modification , 2011, European Journal of Epidemiology.

[27]  H. Braak,et al.  The pathological process underlying Alzheimer’s disease in individuals under thirty , 2011, Acta Neuropathologica.

[28]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[29]  E G Tangalos,et al.  Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.

[30]  Christopher Kircher.  COGNITIVE DECLINE IN INCIDENT ALZHEIMER DISEASE IN A COMMUNITY POPULATION , 2010, Neurology.

[31]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[32]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[33]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[34]  E. Duchesnay,et al.  Longitudinal brain metabolic changes from amnestic Mild Cognitive Impairment to Alzheimer's disease , 2009, NeuroImage.

[35]  Nick C Fox,et al.  Hippocampal atrophy rates in Alzheimer disease , 2009, Neurology.

[36]  C. Jack,et al.  MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.

[37]  D. Schacter,et al.  The Brain's Default Network , 2008, Annals of the New York Academy of Sciences.

[38]  C. Jack,et al.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment , 2008, Neurology.

[39]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[40]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[41]  M. Greicius,et al.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.

[42]  Florence Pasquier,et al.  Tau aggregation in the hippocampal formation: an ageing or a pathological process? , 2002, Experimental Gerontology.

[43]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[44]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[45]  C. Duyckaerts,et al.  Prevalence, Incidence and Duration of Braak’s Stages in the General Population: Can We Know? , 1997, Neurobiology of Aging.

[46]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[47]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.